Chlamydia Infections Treatment Market Size, Share, and Industry Analysis, By Drug (Azithromycin, Doxycycline Hyclate, Tetracycline, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2024-2032

Chlamydia is one of the most common sexually transmitted infections among men and women. Chlamydia trachomatis cause this bacterial infection. It causes pain, a burning sensation during urination, and an abnormal discharge in the area of the urination. Chlamydia often shows no symptoms in the infected individual, and untreated chlamydia can potentially affect the individual. In women, it can lead to pelvic inflammatory disease, ectopic pregnancy, and tubal infertility. Chlamydia can be transmitted through vaginal discharge, semen, genital contact, and unprotected sexual intercourse. It can also be passed from mother to newborn during childbirth.

Chlamydia infections are usually diagnosed with a nucleic acid amplification test using urine or vaginal swab. The treatment for this infection is antibiotics. The common antibiotics for chlamydia are azithromycin, doxycycline hyclate, tetracycline, ofloxacin, and erythromycin ethyl succinate.

The increasing incidence of chlamydia infections and growing awareness among patients about the importance of early diagnosis & treatment are expected to boost the market growth.

• For instance, in July 2019, the Government of Canada launched a five-year action plan on sexually transmitted and blood-borne infections, including chlamydia, to reduce the incidence of these infections.

Moreover, the rising R&D initiatives to increase the accuracy of diagnosis and point-of-care diagnostic kit launches are anticipated to increase the diagnostics rate, which is expected to increase treatment adoption in the near future.

The COVID-19 pandemic disrupted regular checkups owing to the global lockdown, which negatively impacted the market for chlamydia treatment. According to the article published in the journal Sexually Transmitted Diseases in February 2023, prescriptions for chlamydia infection declined by 26.0% from April to May 2020 in Australia. It is due to the initial COVID-19 lockdown, which reduced the number of clinical visits and diagnoses. In 2021, the relaxation of the lockdown resulted in increased doctor visits, diagnostics, and treatment, which boosted the market growth. The global chlamydia infection treatment market is expected to experience stable growth after COVID-19-related pandemic recovery. 

Segmentation

Key Insights

The report covers the following key insights:

• Overview: Regulatory Scenario By Key Countries/ Region


• Incidence of Chlamydia Infection, By Key Countries/ Region, 2023


• Economic Burden of Chlamydia Infection, By Key Countries/ Region, 2023


• Key Industry Developments- Mergers, Acquisitions, and Partnerships


• Impact of COVID-19 on the Market

Analysis by Drug

Based on drug, the market is classified into azithromycin, doxycycline hyclate, tetracycline, and others. The azithromycin segment generated a significant market share. Azithromycin is the most commonly used drug due to its efficiency in controlling the chlamydia trachomatis. Furthermore, the rising number of generic product launches and the rising prevalence of the disease are the factors driving the segment's growth.

• According to WHO, more than 1.0 million STIs are acquired every day. In 2020, WHO estimated 374.0 million new infections of sexually transmitted diseases. Among that, chlamydia was 129.0 million. Such high prevalence and awareness regarding the diagnosis is anticipated to increase the adoption of these devices.

The doxycycline hyclate segment is projected to experience considerable growth in the upcoming years due to the growing awareness among the general population and the high effectiveness of the drug. Moreover, the rising number of generic doxycycline hyclate launches is expected to grow the market in the coming years.

• For instance, in April 2024, Lupin Limited launched Doxycycline Capsules, 40 mg, in the U.S. Such generic product launches are expected to increase the adoption in the near future.

Regional Analysis

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share in 2023. The increase in the incidence of chlamydia infections, coupled with the rise in awareness of diagnosis and treatment, is expected to drive the growth of the market. Additionally, the developments in diagnostics techniques are expected to increase the number of chlamydia infections, which is expected to drive treatment adoption in the region.

• For instance, According to The Centers for Disease Control and Prevention, in 2022, more than 2.5 million cases of chlamydia, syphilis, and gonorrhea were reported in the U.S., in which 1.6 million cases were chlamydia. Such high prevalence is expected to fuel the market growth in the region.

Asia Pacific is expected to witness faster growth in the market due to the growing awareness regarding diagnostics procedures and increasing incidence of chlamydia infection. Moreover, government initiatives to raise awareness of early disease detection and diagnosis are expected to propel market growth in the coming years.

Key Players Covered

• The report includes key players, such as Pfizer Inc., Mayne Pharma, Teva Pharmaceutical Industries Ltd., Mylan Laboratories Inc., Zydus Lifesciences Limited, Dr. Reddy’s Laboratories Ltd., and Lupin Pharmaceuticals, Inc.

Key Industry Developments

• In April 2023, Zydus Lifesciences Limited received FDA approval for azithromycin tablets 500mg to treat infections such as bronchitis, pneumonia, and sexually transmitted diseases, including chlamydia.


• In April 2020, Alembic Limited launched Zithromax, a generic azithromycin with dosage strengths of 250 mg and 500 mg, for the treatment of various bacterial infections, including chlamydia trachomatis.


• In February 2020, Aurobindo Pharma received FDA approval to manufacture and market Azithromycin tablets in the U.S. to treat patients with mild to moderate infections.